Investors who lost money on BioAge Labs, Inc.(BIOA) should contact The Gross Law Firm about pending Class Action - BIOA

Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit following the discontinuation of its STRIDES Phase 2 trial for azelaprag due to safety concerns, leading to a significant drop in its stock price [4]. Group 1: Lawsuit Details - The lawsuit is on behalf of shareholders who purchased BioAge stock during the class period related to its IPO on September 26, 2024 [3]. - The complaint alleges that BioAge's announcement on December 6, 2024, regarding the discontinuation of the trial was unexpected, as the company had previously promoted azelaprag's potential benefits [4]. - Following the announcement, BioAge's stock price plummeted from $20.09 per share to $4.65 per share within a day [4]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by March 10, 2025, to potentially be appointed as lead plaintiffs [5]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [5]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [6]. - The firm aims to ensure companies engage in responsible business practices and seeks recovery for investors affected by misleading statements [6].